维普中文期刊产品整合服务
20篇 您的检索式:作者名="PENHA FM"
    题名 作者 年代 出处 被引量
1Subretinal injection of preservative- free triamcinolone acetonide and supernatant vehicle in rabbits: an electron microscopy study 显示文摘Maia M Penha FM Farah ME 2008Graefe''s Arch Clin Exp Ophthalmol2008,246,:1
2Ability of new vital dyes to stain intraocular membranes and tissues in ocular surgery 显示文摘Rodrigues EB Penha FM Fiod Costa EDP 2010Am J Ophthalmol2010,149,:1
3Subretinal injection of preservative-free triamcinolone acetonide and supernatant vehicle in rabbits:an electron microscopy study显示文摘Maia M Penha FM Farah ME 0,,:1
4Systemic complement inhibition with eculizumab for geographic atro- phy in age-related macular degeneration 显示文摘YEHOSHUA Z De AMORIM GARCIA FILHO CA NUNES RP GREGORI G PENHA FM MOSHFEGHI AA 2014Ophthalmolo- gy2014,121,3:1
5Effect of vital,dyes,on,reti- nal, pigmented epithelial cell viability and apoptosis :implications for chromovitrectomy 显示文摘Penha FM Pons M Costa Ede P 2013Ophthalmologica2013,230,2:1
6Effect of vital dyes on retinal pigmented epithelial cell viability and apoptosis: implica- tions for chromovitrectomy显示文摘Penha FM Pons M Costa Ede P 2013Ophthalmologica2013,2302,:1
7The use of vital dyes in ocular surgery显示文摘Rodrigues EB Costa EF Penha FM 2009Surv Ophthalmol2009,54,:1
8Anterior segment tomography with the cirrus optical coherence tomography显示文摘Rodrigues EB Johanson M Penha FM 0,,:1
9The use of vital dyes in ocular surgery 显示文摘Rodrigues EB Costa EF Penha FM Melo GB BottSs J Dib E 2009Surv Ophthal-mol2009,54,5:1
10Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye) 显示文摘Stewart MW Rosenfeld P J Penha FM 2012Retina2012,32,3:1
11Retinal and ocular toxicity in ocular application of drugs and chemicals - Part Ⅱ: retinal toxicity of current and new drugs显示文摘Penha FM Rodrigues EB Maia M 2010Ophthalmic Res2010,44,4:1
12Retinal and ocular toxic?ity in ocular application of drugs and chemicals-part II: retinal Toxicity of current and new drugs显示文摘Penha FM Rodrigues EB Maia M 2010Ophthalmic Res2010,44,4:1
13Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab,bevacizumab,and aflibercept (vascular endothelial growth factor trap-eye)显示文摘Stewart MW Rosenfeld PJ Penha FM 2012Retina2012,32,3:1
14Pharmacokinetic rationale for dosing ev- ery 2 weeks versus 4 weeks with intravitreal ranibizumab, bev- acizumab, and aflibercept (vascular endothelial growth factor Trap-eye) 显示文摘Stewart MW Rosenfeld P J Penha FM Wang F Yehoshua I Bueno-Lopez E 2012Retina2012,32,3:1
15Ability of new vital dyes to stain intraocular membranes and tissues in ocular surgery显示文摘Rodrigues EB Penha FM de Paula Fiod Costa E Maia M Dib E Moraes M Jr 2010Am J Ophthalmol2010,149,2:1
16Preclinical investigation of the retinal biocompatibility of six novel vital dyes for chromovitrectomy显示文摘Rodrigues EB Penha FM Farah ME de Paula Fiod Costa E Maia M Dib E 2009Retina2009,29,4:1
17Severe retinal thermal injury after indocyanine green-mediated photothrombosis for central serous chorioretinopathy显示文摘Penha FM Aggio FB Bonomo PP 2007Am J Ophthalmol2007,143,5:1
18mediated photothrombesis for central serous chorioretinopathy显示文摘Penha FM Aggio FB Bonomo PP Severe ret inalthermal injury after indocyanine green 0,,05:1
19The use of vital dyes in ocular surgery 显示文摘Rodrigues EB Costa EF Penha FM Melo GB Bottos J Dib E 2009Surv Ophthalmoi2009,54,5:1
20Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevaeizumab,and aflibercept (vascular endothelial growth factor Trap- eye) 显示文摘Stewart MW Rosenfeld PJ Penha FM 2012Retina2012,32,:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费